Farallon Capital Management LLC lowered its position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating) by 1.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,550,000 shares of the biotechnology company's stock after selling 23,829 shares during the quarter. Farallon Capital Management LLC owned 0.07% of Enanta Pharmaceuticals worth $110,329,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. boosted its holdings in Enanta Pharmaceuticals by 1.3% in the first quarter. BlackRock Inc. now owns 3,516,606 shares of the biotechnology company's stock valued at $250,312,000 after acquiring an additional 45,191 shares during the last quarter. State Street Corp boosted its holdings in Enanta Pharmaceuticals by 16.1% in the first quarter. State Street Corp now owns 1,308,586 shares of the biotechnology company's stock valued at $93,145,000 after acquiring an additional 181,517 shares during the last quarter. Fairmount Funds Management LLC boosted its holdings in Enanta Pharmaceuticals by 21.1% in the first quarter. Fairmount Funds Management LLC now owns 469,264 shares of the biotechnology company's stock valued at $33,402,000 after acquiring an additional 81,864 shares during the last quarter. Invesco Ltd. boosted its holdings in Enanta Pharmaceuticals by 18.0% in the first quarter. Invesco Ltd. now owns 342,007 shares of the biotechnology company's stock valued at $24,343,000 after acquiring an additional 52,163 shares during the last quarter. Finally, Soleus Capital Management L.P. boosted its holdings in Enanta Pharmaceuticals by 74.5% in the fourth quarter. Soleus Capital Management L.P. now owns 318,275 shares of the biotechnology company's stock valued at $23,801,000 after acquiring an additional 135,875 shares during the last quarter. Institutional investors and hedge funds own 97.09% of the company's stock.
Get Enanta Pharmaceuticals alerts:Enanta Pharmaceuticals Stock Performance
Shares of NASDAQ ENTA opened at $63.36 on Tuesday. Enanta Pharmaceuticals, Inc. has a 1 year low of $37.59 and a 1 year high of $102.00. The firm has a market cap of $1.31 billion, a price-to-earnings ratio of -10.81 and a beta of 0.55. The stock's 50-day simple moving average is $60.02 and its 200-day simple moving average is $58.61.
Enanta Pharmaceuticals (NASDAQ:ENTA – Get Rating) last announced its earnings results on Monday, August 8th. The biotechnology company reported ($1.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.17). Enanta Pharmaceuticals had a negative return on equity of 32.42% and a negative net margin of 134.21%. The business had revenue of $19.48 million for the quarter, compared to analysts' expectations of $20.73 million. During the same period in the previous year, the firm posted ($1.19) earnings per share. The firm's revenue was down 9.9% compared to the same quarter last year. As a group, research analysts predict that Enanta Pharmaceuticals, Inc. will post -5.75 EPS for the current year.Wall Street Analyst Weigh In
ENTA has been the topic of a number of research analyst reports. Evercore ISI upgraded Enanta Pharmaceuticals from an "in-line" rating to an "outperform" rating and set a $62.00 target price on the stock in a report on Wednesday, July 6th. SVB Leerink raised their price objective on Enanta Pharmaceuticals from $44.00 to $50.00 and gave the company a "market perform" rating in a research report on Monday, August 1st. Oppenheimer raised their price objective on Enanta Pharmaceuticals from $53.00 to $59.00 and gave the company a "market perform" rating in a research report on Wednesday, August 10th. StockNews.com raised Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Wednesday, August 10th. Finally, JMP Securities raised their price objective on Enanta Pharmaceuticals from $103.00 to $137.00 and gave the company a "market outperform" rating in a research report on Tuesday, August 9th. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, Enanta Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $78.63.
Enanta Pharmaceuticals Company Profile
(Get Rating)
Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.
Featured Articles
- Get a free copy of the StockNews.com research report on Enanta Pharmaceuticals (ENTA)
- Do These Dividend Achievers Deserve A Place In Your Portfolio?
- Darden Restaurants Takes the Low Road Against Inflation
- Why These 3 Stocks Are Off to Hot September Starts
- Inflation Doesn't Differentiate, But it's Impact Does
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating).
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.